Breaking News, Financial News

AstraZeneca

AZ posted flat revenues, but a boost in earnings in 2Q09

AstraZeneca 2Q09

2Q Revenues: $8.0 billion (flat)

2Q Earnings: $2.4 billion (+70%)

YTD Revenues: $15.7 billion (flat)

YTD Earnings: $4.0 billion (+21%)

Comments: Two generic marketers of Toprol-XL withdrew from the U.S. market,and the introduction of generic Casodex was delayed, giving AZ a boost. Nexium posted a 6% drop in sales in 2Q09 to $1.2 billion, while Crestor posted a 23% rise to $1.1 billion. Nexium sales rose 12% to $1.2 billion. Seloken/Toprol-XL sales doubled to $417 million. Symbicort sales were up 6% to $551 million.

Sign up today for Contracting & Outsourcing 2009!

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters